Answers are grounded in this paper and cite their sources.
Innovative technology increases tumor control in solid tumors, suggesting new avenues for CAR T cell immunotherapy.
Physical barriers presented by solid tumors limit CAR T cell efficacy. Thus, technologies to increase CAR T cell access to solid tumors could have massive implications in advancing CAR T cell therapies. Here we demonstrate that treatment of solid tumor-bearing mice with our Junction Opener technology and CAR T cells enhances tumor control - potentially enabling CAR T cell immunotherapy for solid tumors.
No takes yet. Share an insight, caveat, or question.
Reed et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: